Moving on? Dispersal policy, onward migration and integration of refugees in the UK

Since 2000, the UK has operated compulsory dispersal, a policy designed to ‘spread the burden’ of housing asylum seekers who require accommodation across the UK and to discourage long-term settlement in London and the South East. To enhance understanding of refugee integration in the UK, this research focuses on the onward migration decisions of those who were dispersed and later granted refugee or humanitarian protection status. To date, much of the dispersal literature has critiqued the policy and focused on the negative outcomes for individuals removed from their networks. This project fills a knowledge gap surrounding the onward migration decisions and integration outcomes of refugees who were dispersed as asylum seekers in the UK

Refugees on the Move: Resettlement and Onward Migration in Final Destination Countries

Refugee migration is often discussed in isolation from other types of mobility. Refugee movement is distinguished by the perception that such migrations are forced and occur among disempowered individuals and populations lacking autonomy. This essay dispels the notion that refugees are not involved in making decisions about their mobility. We situate refugee migration as one category of movement, and then discuss migration trajectories and how individuals determine where they will go and how they will get there. Finally, we discuss refugee resettlement and onward migration, exploring why resettlement does not necessarily stop movement. Many refugees continue to migrate 2 even after resettlement as they search for jobs, co-ethnic communities, a sense of belonging, and so on, which contradicts the policy goals of creating a permanent home in a new country

The Ethical and Practical Challenges of Archiving Refugee Accounts: Reflections from Two Research Projects in the UK

Since the 2015 ‘refugee crisis’, the lens of researchers has been increasingly focused upon asylum seekers and refugees around the world. Nevertheless, working in the field of refugee studies poses several methodological and data challenges. For example, there is a relative paucity of detailed statistical data on refugee stocks, which has led to researchers favouring the collection of personal, qualitative stories from refugee populations. Although this produces a substantial volume of rich narratives, these can be geographically and temporally specific. The collection of qualitative data is also expensive, time consuming, and labour intensive. Therefore, alongside the increasing institutional and mandatory demands to deposit qualitative material in open access repositories, there is growing recognition of the value of archiving refugee accounts. There are also significant challenges in archiving refugee interview transcripts to enhance broader knowledge. In this paper, we discuss the process of archiving refugee accounts to highlight the practical and ethical challenges of depositing sensitive material. Specifically, we draw upon the archival process that was required upon completion of two Research Council funded projects in the UK. This involved the preparation and depositing of interview transcripts from over 100 refugees. Key challenges that arose included the need to uphold interviewees’ confidentiality, the process of anonymisation, and determining the level of access to grant future users. Subsequent issues have involved responding to data requests, permitting selective release of data, and stipulating conditions for release. We then reflect more widely upon the tensions we encountered between procedural and micro-ethics, namely the difference between decisions based upon rules rather than judgement. In doing so, we consider key processes and highlight best practice to be adopted in the future archival of refugee stories

The Effects of Feedback from Aptitude Tests in College Courses on Students’ Academic Self-Perceptions and Planning

It is well documented that there are gender disparities in science, technology, engineering, and mathematics (STEM) fields. Problems with self-efficacy and belonging are established as potential causes of this gap. Previous literature demonstrated that low self-efficacy correlated with high procrastination and, thus, performance. Therefore, it was hypothesized that manipulating feedback on an aptitude test would cause changes in self-efficacy and expected procrastination in undergraduate students. Four hundred eighty-one undergraduate students at the University of Colorado Boulder were recruited and took an aptitude test for a hypothetical class, received manipulated feedback, saw a syllabus for that class, and then answered questions about expected procrastination, self-efficacy, belonging, expected effort, and anticipated grade. Contrary to the hypothesis, results indicated that negative feedback decreased expected procrastination. Further, expected effort mediated the relationship between feedback condition and procrastination, such that participants who received negative feedback on the aptitude test expected greater effort in the class and then planned to procrastinate less. It was also found that students experienced low self-efficacy and belonging in response to negative feedback, but positive feedback did not boost self-efficacy or belonging as compared to no feedback. These effects were amplified in women. Further research in an ecologically valid environment is necessary to affirm the present study&rsquo;s findings, such as an intervention to remove feedback from aptitude tests administered by professors before they teach course material. This could boost self-efficacy and belonging for students starting with less knowledge of the material, without negatively impacting students who are familiar with the material.</p

Sexual Size Dimorphism and Body Condition in the Australasian Gannet

Funding: The research was financially supported by the Holsworth Wildlife Research Endowment. Acknowledgments We thank the Victorian Marine Science Consortium, Sea All Dolphin Swim, Parks Victoria, and the Point Danger Management Committee for logistical support. We are grateful for the assistance of the many field volunteers involved in the study.Peer reviewedPublisher PD

The contribution of coping related variables and cardiac vagal activity on the performance of a dart throwing task under pressure.

The aims of this study were 1) to assess the predictive role of coping related variables (CRV) on cardiac vagal activity (derived from heart rate variability), and 2) to investigate the influence of CRV (including cardiac vagal activity) on a dart throwing task under low pressure (LP) and high pressure (HP) conditions. Participants (n=51) completed trait CRV questionnaires: Decision Specific Reinvestment Scale, Movement Specific Reinvestment Scale and Trait Emotional Intelligence Questionnaire. They competed in a dart throwing task under LP and HP conditions. Cardiac vagal activity measurements were taken at resting, task and during recovery for 5min. Self-reported ratings of stress were recorded at three time points via a visual analogue scale. Upon completion of the task, self-report measures of motivation, stress appraisal, attention, perceived pressure and dart throwing experience were completed. Results indicated that resting cardiac vagal activity had no predictors. Task cardiac vagal activity was predicted by resting cardiac vagal activity in both pressure conditions with the addition of a trait CRV in HP. Post task cardiac vagal activity was predicted by resting cardiac vagal activity in both conditions with the addition of a trait CRV in HP. Cardiac vagal reactivity (difference from resting to task) was predicted by a trait CRV in HP conditions. Cardiac vagal recovery (difference from task to post task) was predicted by a state CRV only in LP. Dart throwing task performance was predicted by a combination of both CRV and cardiac vagal activity. The current research suggests that coping related variables and cardiac vagal activity influence dart throwing task performance differently dependent on pressure condition

Community engagement practices at research centers in U.S. minority institutions: Priority populations and innovative approaches to advancing health disparities research

This paper details U.S. Research Centers in Minority Institutions (RCMI) Community Engagement Cores (CECs): (1) unique and cross-cutting components, focus areas, specific aims, and target populations; and (2) approaches utilized to build or sustain trust towards community participation in research. A mixed-method data collection approach was employed for this cross-sectional study of current or previously funded RCMIs. A total of 18 of the 25 institutions spanning 13 U.S. states and territories participated. CEC specific aims were to support community engaged research (94%); to translate and disseminate research findings (88%); to develop partnerships (82%); and to build capacity around community research (71%). Four open-ended questions, qualitative analysis, and comparison of the categories led to the emergence of two supporting themes: (1) establishing trust between the community-academic collaborators and within the community and (2) building collaborative relationships. An overarching theme, building community together through trust and meaningful collaborations, emerged from the supporting themes and subthemes. The RCMI institutions and their CECs serve as models to circumvent the historical and current challenges to research in communities disproportionately affected by health disparities. Lessons learned from these cores may help other institutions who want to build community trust in and capacities for research that addresses community-related health concerns

Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans

Genome-wide association studies (GWAS) have identified numerous common prostate cancer (PrCa) susceptibility loci. We have fine-mapped 64 GWAS regions known at the conclusion of the iCOGS study using large-scale genotyping and imputation in 25 723 PrCa cases and 26 274 controls of European ancestry. We detected evidence for multiple independent signals at 16 regions, 12 of which contained additional newly identified significant associations. A single signal comprising a spectrum of correlated variation was observed at 39 regions; 35 of which are now described by a novel more significantly associated lead SNP, while the originally reported variant remained as the lead SNP only in 4 regions. We also confirmed two association signals in Europeans that had been previously reported only in East-Asian GWAS. Based on statistical evidence and linkage disequilibrium (LD) structure, we have curated and narrowed down the list of the most likely candidate causal variants for each region. Functional annotation using data from ENCODE filtered for PrCa cell lines and eQTL analysis demonstrated significant enrichment for overlap with bio-features within this set. By incorporating the novel risk variants identified here alongside the refined data for existing association signals, we estimate that these loci now explain ∼38.9% of the familial relative risk of PrCa, an 8.9% improvement over the previously reported GWAS tag SNPs. This suggests that a significant fraction of the heritability of PrCa may have been hidden during the discovery phase of GWAS, in particular due to the presence of multiple independent signals within the same regio

A GWAS in Latin Americans identifies novel face shape loci, implicating VPS13B and a Denisovan introgressed region in facial variation

To characterize the genetic basis of facial features in Latin Americans, we performed a genome-wide association study (GWAS) of more than 6000 individuals using 59 landmark-based measurements from two-dimensional profile photographs and ~9,000,000 genotyped or imputed single-nucleotide polymorphisms. We detected significant association of 32 traits with at least 1 (and up to 6) of 32 different genomic regions, more than doubling the number of robustly associated face morphology loci reported until now (from 11 to 23). These GWAS hits are strongly enriched in regulatory sequences active specifically during craniofacial development. The associated region in 1p12 includes a tract of archaic adaptive introgression, with a Denisovan haplotype common in Native Americans affecting particularly lip thickness. Among the nine previously unidentified face morphology loci we identified is the VPS13B gene region, and we show that variants in this region also affect midfacial morphology in mice

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Background: Abiraterone acetate plus prednisolone (herein referred to as abiraterone) or enzalutamide added at the start of androgen deprivation therapy improves outcomes for patients with metastatic prostate cancer. Here, we aimed to evaluate long-term outcomes and test whether combining enzalutamide with abiraterone and androgen deprivation therapy improves survival. Methods: We analysed two open-label, randomised, controlled, phase 3 trials of the STAMPEDE platform protocol, with no overlapping controls, conducted at 117 sites in the UK and Switzerland. Eligible patients (no age restriction) had metastatic, histologically-confirmed prostate adenocarcinoma; a WHO performance status of 0–2; and adequate haematological, renal, and liver function. Patients were randomly assigned (1:1) using a computerised algorithm and a minimisation technique to either standard of care (androgen deprivation therapy; docetaxel 75 mg/m2 intravenously for six cycles with prednisolone 10 mg orally once per day allowed from Dec 17, 2015) or standard of care plus abiraterone acetate 1000 mg and prednisolone 5 mg (in the abiraterone trial) orally or abiraterone acetate and prednisolone plus enzalutamide 160 mg orally once a day (in the abiraterone and enzalutamide trial). Patients were stratified by centre, age, WHO performance status, type of androgen deprivation therapy, use of aspirin or non-steroidal anti-inflammatory drugs, pelvic nodal status, planned radiotherapy, and planned docetaxel use. The primary outcome was overall survival assessed in the intention-to-treat population. Safety was assessed in all patients who started treatment. A fixed-effects meta-analysis of individual patient data was used to compare differences in survival between the two trials. STAMPEDE is registered with ClinicalTrials.gov (NCT00268476) and ISRCTN (ISRCTN78818544). Findings: Between Nov 15, 2011, and Jan 17, 2014, 1003 patients were randomly assigned to standard of care (n=502) or standard of care plus abiraterone (n=501) in the abiraterone trial. Between July 29, 2014, and March 31, 2016, 916 patients were randomly assigned to standard of care (n=454) or standard of care plus abiraterone and enzalutamide (n=462) in the abiraterone and enzalutamide trial. Median follow-up was 96 months (IQR 86–107) in the abiraterone trial and 72 months (61–74) in the abiraterone and enzalutamide trial. In the abiraterone trial, median overall survival was 76·6 months (95% CI 67·8–86·9) in the abiraterone group versus 45·7 months (41·6–52·0) in the standard of care group (hazard ratio [HR] 0·62 [95% CI 0·53–0·73]; p&lt;0·0001). In the abiraterone and enzalutamide trial, median overall survival was 73·1 months (61·9–81·3) in the abiraterone and enzalutamide group versus 51·8 months (45·3–59·0) in the standard of care group (HR 0·65 [0·55–0·77]; p&lt;0·0001). We found no difference in the treatment effect between these two trials (interaction HR 1·05 [0·83–1·32]; pinteraction=0·71) or between-trial heterogeneity (I2 p=0·70). In the first 5 years of treatment, grade 3–5 toxic effects were higher when abiraterone was added to standard of care (271 [54%] of 498 vs 192 [38%] of 502 with standard of care) and the highest toxic effects were seen when abiraterone and enzalutamide were added to standard of care (302 [68%] of 445 vs 204 [45%] of 454 with standard of care). Cardiac causes were the most common cause of death due to adverse events (five [1%] with standard of care plus abiraterone and enzalutamide [two attributed to treatment] and one (&lt;1%) with standard of care in the abiraterone trial). Interpretation: Enzalutamide and abiraterone should not be combined for patients with prostate cancer starting long-term androgen deprivation therapy. Clinically important improvements in survival from addition of abiraterone to androgen deprivation therapy are maintained for longer than 7 years. Funding: Cancer Research UK, UK Medical Research Council, Swiss Group for Clinical Cancer Research, Janssen, and Astellas